HP-Representation - American Herbal Products Association (AHPA)

Technical Workshops

AHPA regularly presents in-person technical workshops to train the herbal products industry on the latest tools and methods that help ensure high-quality products and compliance with federal and state regulations.

Upcoming Events

AHPA submits GMO labeling recommendations to USDA

AHPA submits GMO labeling recommendations to USDA

USDA proposal would hinder consumer access to information on genetically modified foods

In an effort to ensure American consumers can discern if their food includes GMOs, AHPA recommended significant revisions to a proposed rule issued by USDA's Agricultural Marketing Service (AMS) to establish a mandatory, national bioengineered (BE) food disclosure standard.

Author: AHPA Staff
0 Comments

Seventh Annual Botanical Congress

AHPA's Botanical Congress provides a unique opportunity to learn from herbal industry leaders

November 10, 2018 - SupplySide West - Mandalay Bay -- Las Vegas

Author: AHPA Staff
0 Comments
AHPA represents member interests at Cosmetic Ingredient Review meeting

AHPA represents member interests at Cosmetic Ingredient Review meeting

AHPA attends Cosmetic Ingredient Review meeting finalizing Ginkgo biloba and eucalyptus cosmetic ingredient safety reports

American Herbal Products Association (AHPA) Chief Information Analyst Merle Zimmermann, Ph.D., attended the 147th Cosmetic Ingredient Review (CIR) Expert Panel Meeting on the safety of ingredients used in cosmetics held in Washington, D.C., Jun. 4-5. The meeting included discussions of two CIR safety reports being developed on Gingko biloba and eucalyptus cosmetic ingredients.
0 Comments

AHPA endorses the Hemp Farming Act of 2018

AHPA Board adopts policy to support any state or federal efforts to decriminalize hemp

AHPA is endorsing federal legislation recently introduced to decriminalize hemp and the AHPA Board of Trustees has adopted a policy for the association to support any future state or federal legislation to decriminalize the plant and all its derivatives.
0 Comments

AHPA recommends CBD not be scheduled under any international drug control convention

AHPA submits comments to FDA to inform participation in WHO Expert Committee on Drug Dependence

AHPA submitted comments to the Food and Drug Administration (FDA) yesterday to stress that cannabidiol (CBD) requires no international drug scheduling as an individual substance and encourage the U.S. to support this position.
0 Comments

AHPA supports FDA Guidance making pure or highly concentrated caffeine dietary supplements unlawful

AHPA policy prohibits the sale of pure caffeine

FDA issued guidance titled, "Highly Concentrated Caffeine in Dietary Supplements: Guidance for Industry," to explain that it generally considers pure or highly concentrated caffeine dietary supplements, sold in bulk directly to consumers, to be adulterated because they present a significant or unreasonable risk of illness or injury. The principle in this guidance is consistent with a policy adopted by AHPA members in 2015.
0 Comments

AHPA recommends regulatory improvements in comments submitted to CFSAN

Recommendations seek to reduce regulatory burdens while maintaining consumer protections

The American Herbal Products Association (AHPA) submitted nearly 100 pages of comments today to the Food and Drug Administration (FDA) Center for Food Safety and Applied Nutrition (CFSAN) identifying numerous ways to improve regulations, guidance documents, and enforcement practices to protect public health more effectively and efficiently.
0 Comments
McGuffin statement on Sen. Hatch retirement

McGuffin statement on Sen. Hatch retirement

DSHEA was a remarkable achievement, made possible in large part by Sen. Hatch’s persistence and hard work

American Herbal Products Association (AHPA) President Michael McGuffin issued the following statement regarding the retirement of Sen. Orrin Hatch (R-UT), a vocal dietary supplement advocate who helped shape the laws that regulate the industry.
0 Comments

AHPA submits comments on pre-DSHEA dietary ingredient list

AHPA recommended that FDA make significant changes to previous positions on new dietary ingredients (NDIs)

AHPA's comments were submitted in response to FDA's request for input on issues related to the future development of a list of dietary ingredients marketed in the United States prior to October 15, 1994, when the Dietary Supplement Health and Education Act (DSHEA) became law.
0 Comments

AHPA presents recommendations for pre-DSHEA dietary ingredient list

McGuffin highlights significant issues with FDA's current approach

AHPA President Michael McGuffin stressed that the Food and Drug Administration (FDA) must make some significant changes to previous positions on new dietary ingredients (NDIs) in order to successfully create an authoritative list of old dietary ingredients (ODIs) in a statement delivered yesterday at a public meeting held by FDA to discuss the development of a list of pre-DSHEA dietary ingredients.
Author: AHPA Staff
0 Comments
RSS
123

2018 Annual Fund Sponsors

           

AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.